FDA’s new accelerated pathway may open pharma up to risks, as well as benefits
Faster review times could leave drugmakers vulnerable to litigation, while new Trump administration priorities add more uncertainty to the drug approval process.
Previous Post
What Can We Learn From The FDA's List of Augmented and Virtual Reality Devices? - The Medical Futurist
Next Post
2 Minute Medicine Rewind Aug 25, 2025
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago